Fig. 1

Patient selection flow diagram. Seventy-four patients were eligible for the study after exclusion of patients who had concomitant pancreatic ductal adenocarcinoma (n = 27), who had undergone a total pancreatectomy (n = 4), or had less than 12 months of follow-up after surgery (n = 17). During the follow-up period, recurrence was found in 14 of 74 patients, with recurrent lesions emerging in the remnant pancreas in nine (eight intraductal papillary mucinous neoplasms and one pancreatic ductal adenocarcinoma); the others showed recurrence at other sites